Enzo will work to validate and seek approval for the test pursuant to New York, New Jersey, and CLIA requirements. It will also be responsible for marketing and securing third-party reimbursement for the test.

Enzo is GeneNews’ first U.S. regional marketing partner. ColonSentry is already available in Ontario and offers a noninvasive option for determining an individual’s current risk for colorectal cancer. It identifies telltale RNA biomarkers for early disease in blood samples.

“The greatest barrier to reducing mortality rates arising from colorectal cancer is patient compliance with screening,” according to Bernard Levin, M.D., chair of the GeneNews’ colorectal cancer clinical advisory board. “As a blood-based test, ColonSentry can encourage individuals to undergo screening, which could lead to earlier detection, thereby potentially reducing the suffering and death that can result from this highly treatable disease.”

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

56.6%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.